Dyad gets FDA nod for echocardiography software

2022 08 16 18 41 8211 2022 08 16 Dyad 20220816180414

Dyad Medical's Echo:Prio echocardiography image analysis software has secured U.S. Food and Drug Administration (FDA) 510(k) clearance.

Available on the firm's Libby cloud- and artificial intelligence (AI)-based cardiac imaging analysis platform, Echo:Prio analyzes echocardiography images and serves as a decision-making support tool for index quantification of cardiac function, according to the vendor.

Dyad Medical's Echo:Prio AI-based echocardiography analysis software. Image courtesy of Dyad.Dyad Medical's Echo:Prio AI-based echocardiography analysis software. Image courtesy of Dyad.

It can be used from any location on any device and to provide an immediately available second opinion during interpretation, according to Dyad.

Page 1 of 510
Next Page